HT update: spotlight on estradiol/norethindrone acetate combination therapy

The goal of postmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not...

Descripción completa

Detalles Bibliográficos
Autores principales: Casey, Colleen L, Murray, Christine A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2544373/
https://www.ncbi.nlm.nih.gov/pubmed/18488874
_version_ 1782159180673581056
author Casey, Colleen L
Murray, Christine A
author_facet Casey, Colleen L
Murray, Christine A
author_sort Casey, Colleen L
collection PubMed
description The goal of postmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.
format Text
id pubmed-2544373
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25443732009-05-20 HT update: spotlight on estradiol/norethindrone acetate combination therapy Casey, Colleen L Murray, Christine A Clin Interv Aging Review The goal of postmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy. Dove Medical Press 2008-03 2008-03 /pmc/articles/PMC2544373/ /pubmed/18488874 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Casey, Colleen L
Murray, Christine A
HT update: spotlight on estradiol/norethindrone acetate combination therapy
title HT update: spotlight on estradiol/norethindrone acetate combination therapy
title_full HT update: spotlight on estradiol/norethindrone acetate combination therapy
title_fullStr HT update: spotlight on estradiol/norethindrone acetate combination therapy
title_full_unstemmed HT update: spotlight on estradiol/norethindrone acetate combination therapy
title_short HT update: spotlight on estradiol/norethindrone acetate combination therapy
title_sort ht update: spotlight on estradiol/norethindrone acetate combination therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2544373/
https://www.ncbi.nlm.nih.gov/pubmed/18488874
work_keys_str_mv AT caseycolleenl htupdatespotlightonestradiolnorethindroneacetatecombinationtherapy
AT murraychristinea htupdatespotlightonestradiolnorethindroneacetatecombinationtherapy

Ejemplares similares